Blog

SYNAPS Dx (SDx) is observing November as National Alzheimer’s Disease Awareness Month to support those directly impacted by Alzheimer’s disease and shares the importance of an early and accurate Alzheimer’s diagnosis. November also marks National Family Caregivers Month, which honors those who actively care for family members who require at-home care, including those who suffer from Alzheimer’s. In …

The Centers for Medicare & Medicaid Services (CMS) recently introduced a groundbreaking initiative called the Guiding an Improved Dementia Experience (GUIDE) Model, aimed at enhancing care coordination for Medicare beneficiaries with dementia. The three primary goals of the model are: To improve the quality of life for individuals with dementia Reduce strain on unpaid caregivers …

National Assisted Living Week * September 10 – 16, 2023 SYNAPS Dx (SDx) is observing September 10 – 16 as National Assisted Living Week (NALW) to support those residing in assisted living communities, their families and the selflessness of staff members and volunteers within these communities. The 2023 theme “Season of Reflection” provides the opportunity to properly …

World Alzheimer’s Month and Healthy Aging Month – September 2023 SYNAPS Dx (SDx) is taking this opportunity to raise awareness about the many risk factors associated with Alzheimer’s disease (AD) and the preventative steps needed for risk reduction.  The 2023 theme of World Alzheimer’s Month, ‘Never too early, never too late,’ highlights the importance of taking steps when patients …

Accurate Diagnostic Testing for Alzheimer’s Disease | Business Ninjas: WriteForMe and SYNAPS Dx listen on Apple Podcasts Spotify Google Podcasts Podcast Index Overcast Amazon Music An estimated 6.7 million Americans are living with Alzheimer’s disease, a highly complex disease that is impacting individuals and families and presenting diagnostic challenges to physicians. An accurate diagnosis is critical for ensuring that people get the right treatment as …

The Food and Drug Administration (FDA) historically granted full approval of Leqembi (lecanemab); the second drug indicated to slow the progression of Alzheimer’s disease, which demonstrated a 37% decrease when compared to placebo measured against the AD Cooperative Study-Activities of Daily Living Scale for MCI. Now that the drug has earned full approval, the Centers for Medicare and …

SYNAPS Dx (SDx) a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), recognizes the historic Food and Drug Administration (FDA) approval of Leqembi, the first drug shown to slow the progression of AD. “AD is complex but DISCERN resolves the diagnostic dilemma, enabling physicians to make …

The FDA approved the use of Brexpiprazole (Rexulti) to treat agitation associated with Alzheimer’s disease following the recommendation of the FDA advisory committees. This is the first treatment approved by the FDA to treat agitation associated with Alzheimer’s disease. Agitation associated with Alzheimer’s is a common problem, related to feelings of restlessness and worry that can be brought on by …

Food and Drug Administration (FDA) advisory committee members recently unanimously recommended the full FDA approval of Leqembi (lecanemab) for patients with mild cognitive impairment (MCI) or dementia caused by Alzheimer’s disease.  Leqembi, which currently has accelerated approval as a treatment for Alzheimer’s Disease (AD), shows a 37% decrease when compared to placebo measured against the AD Cooperative Study-Activities of Daily …

The Longest Day of the year, or summer solstice, happens on June 21, 2023. For this reason, the Alzheimer’s Association chose this day to raise awareness across the world about fighting the darkness of Alzheimer’s disease.  This is an opportunity to halt the increased rate of Alzheimer’s misdiagnosis and to shine a light on the physician burden of managing …